Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy

Massimo Breccia, Alessandra Iurlo, Fabrizio Pane, Anna Rita Scortechini, Antonella Russo Rossi, Marco Santoro, Marco Cerrano, Francesca Lunghi, Alessandro Maggi, Nicola Di Renzo, Valeria Sargentini, Alfonso Piciocchi, Claudia Tringali, Alessandra Malato

Open source

DOI: 10.3324/haematol.2026.300586
Published: 2026-05-14
Container: Haematologica
Publisher: Ferrata Storti Foundation (Haematologica)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2026.300586,
  title = {Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy},
  author = {Massimo Breccia and Alessandra Iurlo and Fabrizio Pane and Anna Rita Scortechini and Antonella Russo Rossi and Marco Santoro and Marco Cerrano and Francesca Lunghi and Alessandro Maggi and Nicola Di Renzo and Valeria Sargentini and Alfonso Piciocchi and Claudia Tringali and Alessandra Malato},
  year = {2026},
  journal = {Haematologica},
  doi = {10.3324/haematol.2026.300586},
  url = {https://doi.org/10.3324/haematol.2026.300586}
}

RIS

TY  - JOUR
TI  - Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy
AU  - Massimo Breccia
AU  - Alessandra Iurlo
AU  - Fabrizio Pane
AU  - Anna Rita Scortechini
AU  - Antonella Russo Rossi
AU  - Marco Santoro
AU  - Marco Cerrano
AU  - Francesca Lunghi
AU  - Alessandro Maggi
AU  - Nicola Di Renzo
AU  - Valeria Sargentini
AU  - Alfonso Piciocchi
AU  - Claudia Tringali
AU  - Alessandra Malato
PY  - 2026
JO  - Haematologica
DO  - 10.3324/haematol.2026.300586
UR  - https://doi.org/10.3324/haematol.2026.300586
ER  -

APA

Breccia, M., Iurlo, A., Pane, F., Scortechini, A. R., Rossi, A. R., Santoro, M., Cerrano, M., Lunghi, F., Maggi, A., Renzo, N. D., Sargentini, V., Piciocchi, A., Tringali, C., & Malato, A. (2026). Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy. Haematologica. https://doi.org/10.3324/haematol.2026.300586

Source records

crossref · retrieved 2026-09-26T23:02:33.924Z